Idiopathic Pulmonary Fibrosis (IPF)

NICE Clinical guideline [CG163] Idiopathic pulmonary fibrosis in adults: diagnosis and management. Last updated: May 2017.

Background Information

Interstitial lung disease (ILD): group of lung disorders characterised by inflammation and/or fibrosis of the lung parenchyma - specifically affecting the interstitium - leading to impaired gas exchange and progressive dyspnoea. [Ref]

Idiopathic pulmonary fibrosis (IPF): most common type of ILD, that is of unknown cause (idiopathic), diagnosed by characteristic clinical, radiologic and/or histopathologic features, and by the exclusion of secondary causes . [Ref]

Usual interstitial pneumonia (UIP) pattern: hallmark radiologic and histopathologic pattern required for the diagnosis of IPF. Radiologically, this includes subpleural & basal lung zone predominant honeycombing (clustered cystic airspaces), traction bronchiectasis and ground-glass opacities. The histological pattern includes a patchy, heterogenous fibrosis of the interstitium. [Ref]
 

IPF is the most common type of ILD → global prevalence of ~18 per 100,000 [Ref]

Mean age at diagnosis → ~67-72 years (rare <50 yrs) [Ref]

Sex → Male predominant (2-3:1 M:F ratio) [Ref]

 Although the cause of IPF is unknown, there are several risk factors:
  •  ↑ Age 
  • Male sex 
  • Environmental and occupational exposures: [Ref] ↑ risk with metal dust, wood dust, pesticides, farrming/agricultural work, asbestos exposure 
  • Family History 
  • Conditions (may contribute to disease risk / progression)
    • GORD 
    • OSA
    • Lung disease → emphysema / pulmonary hypertension 
 

IPF presents with typical interstitial lung disease features:

Symptoms 
  • Onset → Insidious (over months - years)
  • Progressive dyspnoea
    • Initially → extertional 
    • Progresses to dyspnoea at rest 
  • Progressive nonproductive cough 
  • Nonspecific → weight loss, fatigue 

Signs / Examination findings 
  • Inspection → digital clubbing (30-50% of cases), cyanosis (advanced disease)
  • Chest auscultation 
    • Fine-inspiratory crackles (velcro-like rales) → indication of pulmonary fibrosis 
      • Distribution → bibasal 
    • Loud inspiratory wheeze (advanced) 
 

Being an ILD, IPF manifests similar to other types of ILD; however, IPF is distinguished by its older age at onset, male predominance and lack of identifiable cause

 

  • Complications overlap between different types of ILD and include: [Ref]
    • Acute exacerbations 
    • Progressive hypoxaemic (type 1) respiratory failure → leading cause of death 
    • Pulmonary hypertension → Cor pulmonale 
    • ↑ risk of lung cancer
 

  • Poor prognosis overall (worst of all ILDs)→ median survival of 3-4 years from diagnosis [Ref]
 
  • Interventions known to improve life expectancy [Ref]
    • Antifibrotic therapy (pirfenidone, nintedanib)
    • Lung transplantation 
 

Diagnosis Guidelines

Perform ALL the following tests if IPF is suspected.
 
Test Purpose Typical findings in IPF
Lung function test - spirometry To distinguish between obstructive vs restrictive lung disease IPF causes a restrictive pattern:
  • FEV1:FVC ratioForced expiratory volume in 1 sec: forced vital capacity ratio
  • FVCForced vital capacity
Lung function test - gas transfer (DLCODiffuse capacity of the lungs for carbon monoxide) Assess gas exchange efficiency DLCODiffusion capacity of the lungs for carbon monoxide is typical of fibrosis
Chest X-ray   Non-specific findings:
  • Bi-basal  and peripheral reticular opacities
  • ↓ Lung volumes
HRCTHigh-resolution CT thorax Gold standard imaging Usual interstitial pneumonia pattern:
  • Traction bronchiectasis
  • Honeycombing

Changes are predominantly in basal and peripheral areas
 

Specialist tests if diagnosis remains uncertain after 1st line tests:
  • Bronchoalveolar lavage
    • Useful to exclude hypersensitivity pneumonitis
 
  • Trans-bronchial biopsy (via bronchoscopy)
 
  • Surgical lung biopsy (usually via VATSVideo-assisted thoracoscopic surgery) - most definitive testing
    • Histology: usual interstitial pneumonia pattern

Management Guidelines

  • Smoking cessation advice
  • Offer pulmonary rehabilitation if appropriate
  • Oxygen therapy as needed
  • Ventilatory support if respiratory failure develops

Management of cough:
  • Treat other causes of cough (e.g. GORDGastro-oesophageal reflux disease, post-nasal drip)
  • Opioids, if the cough is debilitating
  • Thalidomide - to be considered by a specialist if the cough is intractable
 

It is important to optimise treatment of GORDGastro-oesophageal reflux disease in IPF as it is common in IPF patients and can cause microaspiration of gastric contents into the lungs.

Recommended treatment (FVCForced vital capacity 50-80% of predicted)
  • Nintedanib (small molecule tyrosine kinase inhibitor)
  • Pirfenidone (anti-fibrotic and anti-inflammatory agent - via inhibition of TGF-β1)

Oral N‑acetylcysteine is used for managing IPF, but its benefits are uncertain

 

The following are NOT recommended to modify disease progression in IPF:

  • Immunosuppressant (prednisolone, mycophenolate mofetil, azathioprine)
  • Co-trimoxazole
  • Pulmonary vasodilators
    • Endothelin receptor antagonist (bosentan, ambrisentan)
    • Sildenafil
  • Warfarin

All patients with IPF should be considered for lung transplantation if there are no contraindications
  • Discussion and referral should take place 3-6 months after diagnosis or sooner
 

Most patients with IPF will eventually require lung transplantation if they are eligible, as IPF is a progressive, fatal disease with a median survival of ~3 years after diagnosis without transplant.

Lung transplantation offers a substantial improvement in survival (5-year post-transplant survival is ~50-55%).

Author: Adams Lau
Reviewer:
Last edited: 27/08/25